Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Vorolanib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EyePoint Reports Positive Results for Duravyu in Macular Edema
    EyePoint Reports Positive Results for Duravyu in Macular Edema

    05 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/05/3021051/0/en/EyePoint-Announces-Positive-Six-Month-Results-for-the-Phase-2-VERONA-Clinical-Trial-of-DURAVYU-for-Diabetic-Macular-Edema-Meeting-Primary-and-Secondary-Endpoints.html

    GLOBENEWSWIRE
    05 Feb 2025
    Share Share
    EyePoint Pharmaceuticals to Highlight DURAVYU (Vorolanib) Clinical Progress
    EyePoint Pharmaceuticals to Highlight DURAVYU (Vorolanib) Clinical Progress

    26 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/26/2904464/0/en/EyePoint-Pharmaceuticals-to-Highlight-DURAVYU-vorolanib-intravitreal-insert-Clinical-and-Regulatory-Progress-and-Pipeline-Innovation-at-R-D-Day-2024.html

    GLOBENEWSWIRE
    26 Jun 2024
    Share Share
    EyePoint Shows Updated Positive Interim Data from Phase 1 Trial of EYP-1901
    EyePoint Shows Updated Positive Interim Data from Phase 1 Trial of EYP-1901

    12 Feb 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/eyepoint-pharmaceuticals-announces-updated-positive-interim-safety-and-efficacy-data-from-ongoing-phase-1-davio-clinical-trial-evaluating-eyp-1901-for-the-treatment-of-wet-amd-301481159.html

    PRNEWSWIRE
    12 Feb 2022
    Share Share
    EyePoint Reports +ve Interim Safety & Efficacy Data from EYP-1901 Phase 1 Trial
    EyePoint Reports +ve Interim Safety & Efficacy Data from EYP-1901 Phase 1 Trial

    14 Nov 2021

    // PIPELINEREVIEW

    https://pipelinereview.com/index.php/2021111479688/Small-Molecules/EyePoint-Pharmaceuticals-Reports-Positive-Interim-Safety-and-Efficacy-Data-from-Phase-1-DAVIO-Clinical-Trial-Evaluating-EYP-1901-for-the-Treatment-of-Wet-AMD.html

    PIPELINEREVIEW
    14 Nov 2021
    Share Share